HomeMy WebLinkAboutBenton Franklin Health District - MOU for COVID-19 Vaccination Services 03.15.2021PUBLIC ! I I I
MaMTM
Prarant - Promate • Protect
30
MEMORANDUM OF UNDERSTANDING
Between
BENTON-FRANKLIN HEALTH DISTIRCT
And
CITY OF PASCO — FIRE DEPARTMENT
This Memorandum of Understanding (MOU), by and between Benton -Franklin Health District (BFHD) doing business at
7102 W. Okanogan Place, Kennewick, WA 99336, and City of Pasco—Fire Department collectively known as the "Parties"
is being executed for the purpose of providing COVID-19 Vaccines for mass vaccination clinics.
EFFECTIVE DATES: March 15, 2021—December 31, 2021
ORGANIZATIONAL CONTACT INFORMATION
Benton -Franklin Health District Phone: (509) 46D-4200
7102 W. Okanogan Place Fax: (509) 460.4590
Kennewick, WA 99336
Title/Responsibility
Contact Name
Phone
Fax
Email
Administrator/Signature Authority
Jason Zaccaria
509.460-4567
5094604590
lasonzPbfhd.wa.gov
Contracts Manager
Bonnie Hall
5094604553
509.460-4590
8onnleh(4lbfhd.wa.gov
Crowlevm(eoasco-wa.gov
Sr. Manager—Surveillance &
Investigations
Rick Dawson
509-460-4313
509-460.4515
RickdPbfhd.wa.gov
Vaccine Coordinator
Miriam Chaviano
509-460-4226
509-460-4590
Miriamcg6tifhd.wa.eov
Technical Planning Coordinator
Sierra Knutson
5094604533
509460-0590
Sieraktmbfhd.wa.gov
City of Pasco Phone: (509) 545-3426
101 E. Ainsworth Ave. Fax: (509) 543-5717
Pasco, WA 99301
Responsibility
Contact Name
Phone
Email
Signature Authority—City Manager
Dave Zabell
509.545-5404
tabellditasco-wa.gov
Fire Chief—Primary Contact
Bob Gear
GearbiSoasco-wa-gov
Program Manager
Michelle Crowley
509-543-5702
Crowlevm(eoasco-wa.gov
Finance Director
Richa Sigdel
509-544-3065
5iedelrPoasco-wa.gov
Rhonda Riggle — Admin
Rhonda Riggle
509.543-5709
Riggler@oasco-wa,gov
MOU aty of Pasw Vacclne Distdbullon 2021—Page 1
Whereas, the aforementioned Parties desire to enter into this agreement in which they shall work together to
accomplish the goals and objectives set forth;
And Whereas, the Parties are desirous to enter an understanding, thus setting out the working arrangements that both
Parties agree shall be necessary to complete this partnership;
MISSION
This partnership is being established with the intended mission to increase access to COVID-19 vaccinations for the
residents of Benton and Franklin Counties.
PURPOSE AND SCOPE
The Parties intend for this MOU to provide the cornerstone and structure for the activities and any further impending
binding contract which may be related to this partnership. This agreement is for the purposes of mobile vaccination
clinics and is not intended for ongoing vaccine supply.
District Health Officer: The Benton -Franklin Health District Health Officer, Dr. Amy Person will provide the standing
orders and processes for the specific vaccines to be given.
EMS Medical Director: The EMS Medical Director will provide medical oversight, authority and direct the training
protocols for EMS staff to be able to administer injections.
Public Readiness and Emergency Preparedness Act (PREP Act) Deciaration': The PREP Act Declaration issued a fifth
amendment on January 28, 2021 which provides additional categories of qualified persons authorized to prescribe,
dispense, and administer COVID-19 vaccines authorized by the US Food and Drug Administration.
SERVICES COOPERATION
Benton -Franklin Health District shall render and provide the following services that may include, but are not limited
to:
• Provide for the selection, ordering and receiving of COVID-19 vaccine
• Provide and maintain appropriate cold storage and temperature monitoring equipment for the COVID-19
vaccine off-site and on-site at the vaccination clinics
• Serve as the ordering provider for the vaccine and provide standing vaccination orders
• Provide training and technical support on the PREPMOD documenting and scheduling system
• Provide vaccine storage and handling resources, such as the CDC Vaccine Storage and Handling Toolkit as they
become available. mos•//www cdc pov/vaccines/hcg/admin/storage/toolkit/storage-handling-toolkit.i)df
• Develop and supply digital versions of educational materials as requested
• Provide access to a vaccine coordinator who will provide technical assistance with regard to planning,
documentation, and transportation.
• Complete vaccine loss log
City of Pasco Fire Department shall render and provide the following services that Include, but are not limited to:
• Provide staffing for the vaccination events including appropriately credentialed vaccine providers
MOu City of Pnw Waine DiSidbutlon 2021—Page 2
• The mobile teams shall contact the BFHD Technical Planning Coordinator (page 1) to arrange pickup of the
vaccine and auxillary kits located at 7102 W Okanogan Pl, Kennewick, WA 99336. All vaccine that has been
opened must be used by the end of the day per the vaccine management guldellnes.
• Ensure vaccine providers are appropriately training In COVID-19 vaccine administration
• Supply the logistical equipment needed for carrying out a vaccination event
• Provide a facility for holding the vaccination event
• Use PrepMod for scheduling needs
• Document all vaccines given in PrepMod
• Complete and provide patients with CDC vaccine cards
• Will be responsible for the printing and distribution of educational materials as developed by BFHD
• Provide approved Mass Vaccine Plan that includes safety plans, monitoring guidelines, and procedure for
avoiding waste (standby Ilst, anyone Is eligible In current iters).
• Identify a site manager for each event that will provide oversite of the vaccine dinic and ensure adherence to
the Mass Vaccine plan
• Provide onsite monitoring so the vaccine Is maintained within the required temperature and handling thresholds
• Develop a vaccine plan that will allow for flexible scheduling to accommodate changes in supply availability that
may be limited less than one week advance notice.
• Plan for and provide both 14 and V dose mass vaccine clinics at appropriately timed Intervals
• Use the most current guidance and best practices documents from the CDC (see link to toolkit above)
• if vaccine went out of appropriate temperature ranges, follow the Vaccine Temperature Excursion Guide
(Exhibit A) attached.
• Distribute the current Vaccine information Statements (Exhibit B) each time a vaccine is administered and
maintain records In accordance with the National Childhood Vaccine Injury Act (NCVIA), which Includes
reporting clinically significant adverse events to the Vaccine Adverse Event Reporting System (VAERS).
The term of this MOU shall be from March 15, 2021 to December 31, 2021 and may be extended upon written
agreement of both Parties.
CONSIDERATM
No funds will be exchanged between the parties for under this MOU. Both parties will work collectively for the benefit
of the community and seek funding for their respective agencies through other sources to fulfill their obligations under
this MOU.
DATA USE OWNERgHIP AND DI , URE
Information provided to BFHD by City of Pasco Fire Department will be used for all necessary public health efforts as
outlined In WAC 246-101. This will Include sharing PHI under legally allowable ways for the purpose of protecting the
health of the public as well as congregate data for public disclosures.
AMBIDIMUMgRCANCKMONOFIMSMBWNMUMOFUNOMANDlNG
This MOU may be amended or modified at any time In writing by mutual consent of both parries. In addition, this MOU
may be cancelled by either party with 15 days advance written notice, with the exception where cause for cancellation
MOU Qty of Pasco VaWw Ot WbWan 2023 —Page 3
may Include, but Is not limited to, a material and significant breach of any of the provisions contained herein, when it
may be cancelled upon delivery of written notice to the other party.
GENERAL PAaVi ONS
The Parties acknowledge and understand that they must be able to fulfill their responsibilities under this MOU in
accordance with the provisions of the law and regulations that govern their activities. Nothing In the Memorandum is
Intended to negate or otherwise render Ineffective any such provisions or operating procedures. The Parties assume full
responsibility for their performance under the terms of this agreement.
If at any time elther party is unable to perform their duties or responsibilities under this MQU consistent with such
party's statutory and regulatory mandates, the affected party shall Immediately provide written notice to the other
party to establish a date for resolution of the matter.
LIMITATION OF UARILRY
No rights or limitations of rights shall arise or be assumed between the Parties because of the terms of this MOU.
man
Any notice or communication required or permitted under this MOU shall be sufficiently given if delivered In person, by
email, or certified mall, return receipt requested, to the address set forth on page one (1) of this MOU or to such
address as one may have furnished to the other In writing.
GUUERNING IAW
This MOU shall be governed by and construed In accordance with the laws of the State of Washington.
SEVERABILITY CLAUSE
In the event that any provision of this MOU shall be deemed to be severable or Invalid, and if any term, condition,
phrase, or portion shall be determined to be unlawful or otherwise unenforceable, the remainder of the MOU shall
remain in full force and effect, so long as the clause severed does not affect the intent of the parties. If a court should
find any provision of this MOU to be Invalid or unenforceable, but that by limiting said provision it would become valid
and enforceable, then said provision shall be deemed to be written, construed, and enforced as so limited.
ASSIGNMENT
Neither party to this MOU may assign or transfer the responsibilities or agreement made herein without the prior
written consent of the non assigning party, which approval shall not be unreasonably withheld.
This MOU constitutes the entire understanding of the Parties pertaining to all matters contemplated hereunder at this
time. The Parties signing this MOU desire or Intend that any Implementing contract, license, or other agreement entered
Into between the Parties subsequent hereto shall supersede and preempt any conflicting provision of this MOU whether
written or oral.
MOU SUMMARIZATION
Furthermore, the Parties to this MOU have mutually acknowledged and agreed to the following:
MOU City of Pasco Vacdns oistet kiftn 20n — Page 4
✓ The Parties shall work together in a cooperative and coordinated effort, and In such a manner and fashion to
bring about the achievement and fulfillment of the goals and objectives of this partnership.
✓ It is not the Intent of this MOU to restrict the Parties to this Agreementfrom their Involvement or partldpation
with any other public or private Individuals, agencies, or organizations.
✓ The Parties to this MOU shall mutually contribute and take part In any and all phases of the planning and
development of this partnership, to the fullest extent possible.
✓ It is not the Intent or purpose of this MOU to create arty rights, benefits, and/or trust responsibglties by or
between the parties.
✓ The Parties to this MOU have the right to Individually or jointly terminate their participation in this Agreement
provided that advanced written notice Is delivered to the other party.
AUTHORIZATION AND EKECUTION
The signing of this Memorandum of Understanding does not constitute a formal undertaking, and as such it simply
Intends that the signatories shall strive to reach, to the best of their abilities, the goals and objectives stated in this
MOU.
Jason Zaccaria—Adminlstrator Date
MOu aW tf Pastevattare 06Mb1nm 2021—PW s
CITY OF PASCO — FIRE DEPARTMENT
`
3•rz.2r
Dave
n fiYManager Date
WASHINGTON STATE
eon
Childhood Vaccine Program
Office of Immunization and Child Profile 1 (360) 236-2829 1 doh.wa.gov/cvp
DOCUMENT
i
1
CONTACT
t
r \
I CORRECT 1
s
Exhibit A
(Health
wachlldhoodvaccines@doh.wa.gov
Vaccine Temperature Excursion Guide
Notify the primary or backup vaccine coordinator immediately if you discover a
temperature excursion.
Bag the affected vaccines and place a label on them saying "DO NOT USE." Do
not discard these vaccines or remove them from the storage unit.
Document the details of the temperature excursion including the:
• Date and time
• Storage unit temperature
• Description of the event
• Determine the length of time the vaccine has been out of range
• Inventory vaccines affected
• Name of the person completing the report
• Submission of the DOH Vaccine Loss Log
If viability cannot be determined based
on the manufacturer's package insert,
contact the manufacturer directly. Be
prepared to provide documentation and
data logger data. Follow manufacturer
guidance based on viability of vaccines.
If manufacturer guidance is unclear,
contact the Childhood Vaccine Program
at WAChildhoodVaccines@doh.wa.gov
with the manufacturer results to
determine next steps
_1
Mer&
1 -SOD -672.6372
Sanon Pasteur
1.800.822-2463
Glaxo5milhOnt
1-888-825.5249
Phrer
1.800-438-1985
segirus
1.855-358.8966
AstraZeneca
1-800-236-9933
IMedlmmuntl
Masseiolodirs iGnlolsi
1-617 474.3000
Determine and address what caused the temperature issue. Check the basics,
including the power supply, the unit door, and thermostat settings.
If the excursion was the result of a temperature fluctuation, follow guidance on
adjusting the storage unit temperature to the correct range.
if the thermometer failed, implement your back-up thermometer.
If the storage unit failed, implement your emergency plan.
To request this document in another format, call 1-800-525-0127. Deaf or hard of hearing
customers, please call 711 (Washington Relay) or email civll.rights@doh.wa.gov. DOH 348-708 January 2020.
WHAT SHOULD YOU MENTION TO YOUR VACCINATION PROVIDER BEFORE
YOU GET THE JANSSEN COVID-19 VACCINE?
Tell the vaccination provider about all of your medical conditions, including if you:
• have any allergies,
• have a fever,
• have a bleeding disorder or are on a blood thinner,
• are immunocompromised or are on a medicine that affects your immune system,
• are pregnant or plan to become pregnant,
• are breastfeeding,
• have received another COVED -19 vaccine,
WHO SHOULD GET THE JANSSEN COVM-19 VACCINE?
FDA has authorized the emergency use of the Janssen COVED49 Vaccine in individuals 18 years
of age and older.
WHO SHOULD NOT GET THE JANSSEN COVED -19 VACCINE?
You should not get the Janssen COVID49 Vaccine if you:
• had a severe allergic reaction to any ingredient of this vaccine.
WHAT ARE THE INGREDIENTS IN THE JANSSEN COVED -19 VACCINE?
The Janssen COVID-19 Vaccine includes the following ingredients: recombinant,
replication -incompetent adenovirus type 26 expressing the SARS-CaV 2 spike protein, citric acid
monohydrate, trisodiwn citrate dfydrate, ethanol, 2 hydroxypropyl-p-cyclodextrin (HBCD),
polysorbate-80, sodium chloride.
HOW IS THE JANSSEN COVID 49 VACCINE GIVEN?
The Janssen COVED -19 Vaccine will be given to you as an injection into the muscle.
The Janssen COVED -19 Vaccine vaccination schedule is a single dose.
HAS THE JANSSEN COVED -19 VACCINE BEEN USED BEFORE?
The Janssen COVID-19 Vaccine is an unapproved vaccine. In an ongoing clinical trial, 21,895
individuals 19 years of age and older have received the Janssen COVED -19 Vaccine.
Exhibit S
FACT SHEET FOR RECIPIENTS AND CAREGIVERS
EMERGENCY USE AUTHORIZATION (EUA) OF
THE JANSSEN COVID-19 VACCINE TO PREVENT CORONAVIRUS DISEASE 2019
(COVID-19) IN INDIVIDUALS 18 YEARS OF AGE AND OLDER
You are being offered the Janssen COVID-19 Vaccine to prevent Coronavirus Disease 2019
(COVID-19) caused by SARS-CoV-2. This Fact Sheet contains information to help you
understand the risks and benefits of receiving the Janssen COVID-19 Vaccine, which you may
receive because there is cumeotly a pandemic of COVID-19.
The Janssen COVID-19 Vaccine may prevent you from getting COVID-19. There is no U.S. Food
and Drug Administration (FDA) approved vaccine to prevent COVID-19.
Read this Fact Sheet for information about the Janssen COVID-19 Vaccine. Talk to the vaccination
provider if you have questions. It is your choice to receive the Janssen COVID-19 Vaccine.
The Janssen COVID-19 Vaccine is administered as a single dose, into the muscle.
The Janssen COVID-19 Vaccine may not protect everyone.
This Fact Sheet may have been updated. For the most recent Fact Sheet, please visit
www ianssencovid19yaccimoAxn.
WHAT YOU NEED TO KNOW BEFORE YOU GET THIS VACCINE
WHAT IS COVIW19?
COV049 is caused by a coronavirus called SARS-CoV-2. This type of coronavirus has not been
seen before. You can get COVID-19 through contact with another person who has the virus. It is
predominantiy a respiratory illness that can affect other organs. People with COVID-19 have had
a wide range of symptoms reported, ranging from mild symptom to severe illness. Symptoms
may appear 2 to 14 days after exposure to the virus. Common symptoms may include: fever or
chills; cough; shortness of breath; fatigue; muscle or body aches; headache; new toss of taste or
smell; sore throat; congestion or runny arose; nausea or vomiting; diarrhea
WHAT IS THE JANSSEN COVID-19 VACCINE?
The Janssen COVID-19 Vaccine is an unapproved vaccine that may prevent COVID49. There is
no FDA -approved vaccine to prevent COVID-19.
The FDA has authorized the emergency use of the Janssen COVID-19 Vaccine to prevent
COVED -19 in individuals 18 years of age and older under an Emergency Use Authorization
(EUA).
For more information on EUA, see the "What Is an Emergency Use Authorization (EUA)?"
section at the end of this Fact Sheet.
R Cade
Fact Sheets Website
Tet hone numbers
MEN
i
www.jmmenwvidl9vaceine com.
US Toll Frew. 1-900-5654009
US Toll: (908) 455-9922
HOW CAN I LEARN MORE?
Ask the vaccination provider.
• Visit CDC at https://www.cdc.gov/coronavirus/2019-ncovrmdox.btml.
• Visit FDA at https://www.fda.gov/emergency-preparedness-and-response/mcm4egal-
regulatory-and policy-fiamework/emergency-use-authorization.
Contact your local or state public health department.
WHERE WILL MY VACCINATION INFORMATION BE RECORDED?
The vaccination provider may include your vaccination information in your state/local
jurisdiction's Immunization Information System (IIS) or other designated system. For more
information about IISs visit: https://www.cdc.govtvaocines/progran iWabout html.
WHAT IS THE COUNTERMEASURE INJURY COMPENSATION PROGRAM?
The Countermeasures Injury Compensation Program (CICP) is a federal program that may help
pay for costs of medical care and other specific expenses for certain people who have been
seriously injured by certain medicines or vaccines, including this vaccine. Generally, a claim must
be submitted to the CICP within one (1) year from the date of receiving the vaccine. To learn more
about this program, visit www.hrso.gov/cicp or call 1-855-266-2427.
WHAT IS AN EMERGENCY USE AUTHORIZATION (EUA)?
The United States FDA has made the Janssen COVID-19 Vaccine available under an emergency
access mechanism called an EUA. The EUA is supported by a Secretary of Health and Human
Services (HHS) declaration that cinumstances adst to justify the emergency use of drugs and
biological products during the COVED- 19 pandemic.
The Janssen COVID-19 Vaccine has not undergone the same type of review as an FDA -approved
or cleared product. FDA may issue an EUA when certain criteria are met, which includes that there
are no adequate, approved, and available alternatives. In addition, the FDA decision is based on
the totality of scientific evidence available showing that the product may be effective to prevent
COVID-19 during the COVID-19 pandemic and that the known and potential benefits of the
product outweigh the known and potential risks of the product All of these criteria must be met to
allow for the product to be used during the COVID-19 pandemic.
The EUA for the Janssen COVED -19 Vaccine is in effect for the duration of the COVED -19
declaration justifying emergency use of these products, unless terminated or revoked (alter which
the products may no longer be used).
MmufacW&I by:
Janssen Biotech, Inc.
a Janssen Pharmaceutical Company of Johnson & Johmn
Horsham, PA 19044, USA
.....a
Janssen fiA--
®2021 Janssen Phannec m ical Companies
F& taa+e kftttf m. =U US Toll Fm 1-800tiS65.40M US Tdk (908 45S -M w go Eo warw jso =vW Ift oefnt
Revised: Fab27MI
Sm to capture that this Fact Sheet was provided to va cine
t�cipiettt for the elecxt+onic medical recvrdslimmunisatian
information systems.
Bade l� 0?J2021